FDA limits research of former AHA president for submitting false information

[Guest guest]

Sounds like the standard practice. Then he was put in as the president of the

American Heart Association. Go figure.

 

http://bmj.com/cgi/content/full/325/7377/1377/a

 

BMJ 2002;325:1377 ( 14 December )

 

NewsFDA limits research of former AHA president for submitting false information

Janice Hopkins Tanne, New York

Just days before he completed his year as president of the American Heart

Association on 30 June, Dr David Faxon signed a consent agreement with the Food

and Drug Administration limiting his clinical research.

 

On 19 June 2002 Dr Faxon agreed that for three years he would not be the

principal investigator for more than two FDA regulated clinical investigations

at any one time, and that he would not be the principal clinical investigator

for a study that enrolled more than 25 subjects.

 

The agreement follows an investigation into Dr Faxon's work, which was held from

October to November in 1999 when he was chief of cardiology at the University of

Southern California in Los Angeles. The FDA inspected his clinical study,

comparing a new drug with aspirin to see which gave better protection from

ischaemic heart events after acute coronary syndromes.

 

After its investigation, the FDA complained that Dr Faxon failed to personally

conduct or supervise the clinical investigation, that he submitted false

information to the trial sponsor, and that he failed to conduct the study in

accordance with the approved protocol. He was also found not to have kept

adequate and accurate case histories and not to have provided a Spanish version

of the informed consent document to people whose first language was Spanish, not

English.

 

The complaint cited examples of records being falsified to alter the duration of

chest pain; changes in the records that led to the inclusion of patients who

were not eligible for inclusion; patients being included despite being enrolled

after the time limits; patients being included when they were receiving drugs

that should have excluded them.

 

Dr Faxon answered the FDA in December 1999, saying his study's coordinator was

responsible for misrepresentation of data and he had no knowledge of the

practice. The FDA rejected his response: " We remind you that you are responsible

for personally conducting and supervising the clinical investigations since you

are the investigator of record. Therefore, we consider your explanation

unacceptable. "

 

In April 2000, the FDA sent Dr Faxon a " Notice of Initiation of Disqualification

Proceedings and Opportunity to Explain (NIDPOE). " Few clinical investigators

receive such a notice. In 2000, Dr Faxon was one of only six to receive one. In

2001 there were four, and so far this year there have been two.

 

In July 2000, Dr Faxon became section chief of cardiology and professor of

medicine at the University of Chicago.

 

 

 

 

 

 

 

 

Gettingwell- / Vitamins, Herbs, Aminos, etc.

 

To , e-mail to: Gettingwell-

Or, go to our group site: Gettingwell

 

 

 

 

Mail Plus - Powerful. Affordable. Sign up now